Shanghai Xuerong Bio-Technology Co Ltd (300511) - Total Liabilities
Based on the latest financial reports, Shanghai Xuerong Bio-Technology Co Ltd (300511) has total liabilities worth CN¥2.43 Billion CNY (≈ $356.26 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Xuerong Bio-Technology Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Shanghai Xuerong Bio-Technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Shanghai Xuerong Bio-Technology Co Ltd to evaluate the company's liquid asset resilience ratio.
Shanghai Xuerong Bio-Technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Xuerong Bio-Technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sterling and Wilson Renewable Energy Limited
NSE:SWSOLAR
|
India | Rs46.66 Billion |
|
Huasu Holdings Co Ltd
SHE:000509
|
China | CN¥666.23 Million |
|
Electra Real Estate Ltd
TA:ELCRE
|
Israel | ILA582.26 Million |
|
Ho Tung Chemical Corp
TW:1714
|
Taiwan | NT$6.89 Billion |
|
Sijin Intelligent Forming Machinery
SHE:003025
|
China | CN¥296.09 Million |
|
Sung Kwang Bend Co.Ltd
KQ:014620
|
Korea | ₩40.94 Billion |
|
Investors Title Company
NASDAQ:ITIC
|
USA | $88.65 Million |
|
Delpha Construction Co Ltd
TW:2530
|
Taiwan | NT$20.39 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Shanghai Xuerong Bio-Technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shanghai Xuerong Bio-Technology Co Ltd total assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Xuerong Bio-Technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Xuerong Bio-Technology Co Ltd (2012–2024)
The table below shows the annual total liabilities of Shanghai Xuerong Bio-Technology Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.03 Billion ≈ $443.56 Million |
-4.37% |
| 2023-12-31 | CN¥3.17 Billion ≈ $463.84 Million |
+29.58% |
| 2022-12-31 | CN¥2.45 Billion ≈ $357.96 Million |
-8.91% |
| 2021-12-31 | CN¥2.69 Billion ≈ $392.99 Million |
+5.66% |
| 2020-12-31 | CN¥2.54 Billion ≈ $371.94 Million |
+20.92% |
| 2019-12-31 | CN¥2.10 Billion ≈ $307.59 Million |
-9.50% |
| 2018-12-31 | CN¥2.32 Billion ≈ $339.86 Million |
-4.03% |
| 2017-12-31 | CN¥2.42 Billion ≈ $354.13 Million |
+106.71% |
| 2016-12-31 | CN¥1.17 Billion ≈ $171.31 Million |
+3.44% |
| 2015-12-31 | CN¥1.13 Billion ≈ $165.61 Million |
+10.99% |
| 2014-12-31 | CN¥1.02 Billion ≈ $149.21 Million |
-1.00% |
| 2013-12-31 | CN¥1.03 Billion ≈ $150.72 Million |
+0.11% |
| 2012-12-31 | CN¥1.03 Billion ≈ $150.55 Million |
-- |
About Shanghai Xuerong Bio-Technology Co Ltd
Shanghai Xuerong Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research and development, cultivation and sale of fresh edible mushrooms in the People's Republic of China. It offers enoki mushrooms; shiitake mushrooms, including oyster mushrooms, white jade mushrooms and seafood mushrooms; king oyster mushrooms; and velvet mushrooms, as well as Pleurotus eryngii and Flammu… Read more